


Amendments to the Claims:

Listing of Claims:

Claims 1-16 (canceled)

Claim 1 (new): A method of treating a warm-blooded animal having myeloma comprising an epothilone of formula I



wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,
or a pharmaceutically acceptable salt thereof.

Claim 2 (new): The method according to claim 1 wherein the warm-blooded animal is a human.

Claim 3 (new): The method according to claim 1 wherein the myeloma is resistant to conventional cytotoxic chemotherapy.

Claim 4 (new): The method according to claim 1 wherein overexpression of the multi-drug resistance protein p170 is observed.

Claim 5 (new): The method according to claim 1 wherein the myeloma is resistant to a taxane, e.g., paclitaxel.


Claim 6 (new): The method according to claim 1 wherein the disease is multiple myeloma.

Claim 7 (new): The method according to claim 1 wherein the compound of formula I is epothilone B.

Claim 8 (new): The method according to claim 7 comprising administering epothilone B weekly in a dose that is between about 0.1 to 6 mg/m² for three weeks after an interval of one to six weeks after the preceding treatment.

Claim 9 (new): The method according to claim 1 wherein A is O; R is methyl; R' is methylthio; and Z is O.

Claim 10 (new): A combination comprising (a) an epothilone of formula I



wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, and (b) at least one compound selected from the group consisting of alkylating agents, corticosteroids and anthracyclines, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use in the treatment of myeloma.

Claim 11 (new): The combination according to claim 10 wherein the epothilone is epothilone B.

Claim 12 (new): The combination according to claim 10 wherein A is O; R is methyl; R' is methylthio; and Z is O.

Claim 13 (new): The combination according to claim 10 for simultaneous, separate or sequential use in the treatment of multiple myeloma.

Claim 14 (new): The combination according to claim 10 for the preparation of a medicament for the treatment of myeloma.

Claim 15 (new): The combination according to claim 10 which is jointly therapeutically effective against myeloma to a warm-blooded animal in need thereof.

Claim 16 (new): A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against myeloma, of a combination according to claim 10 and at least one pharmaceutically acceptable carrier.

Claim 17 (new): A commercial package comprising a combination as defined in claim 10, together with instructions for simultaneous, separate or sequential use thereof in the treatment of myeloma.